manop-shutterstock-com
manop / Shutterstock.com
27 January 2016AmericasJenny Shmuel and Megan Chacon

Diagnostics patent eligibility: a turning point approaches

The patent eligibility landscape under 35 USC §101 has shifted in the past few years, with the courts issuing a series of decisions which threaten to undermine a system designed to encourage and reward innovation and development. The application of this law in one particular area—screening and diagnostic testing during and after pregnancy—highlights the unprecedented difficulty faced by those seeking patent protection in the life sciences arena and points to a potential turning point in the law.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
9 January 2026   A busy week in US courts saw major pharma companies and biotech firms move to protect key therapies and research tools, with new lawsuits over migraine and cancer drug generics, and alleged misuse of COVID-19 vaccine tech.
Americas
8 January 2026   Important questions about when companies must act on suspicions of theft and whether damages can stack with injunctions were raised in a dispute that has already sent ripples across med tech.
Americas
8 January 2026   Crop science division alleges that vaccine developers used patented mRNA stability technology in shots that earned them around $140 billion in global sales.